Obesity and Obesity-related Medical ConditionsREDONCT06857578
Revision Surgery for Suboptimal Weight Loss or Recurrent Weight Gain After Roux-en-Y Gastric Bypass
A study testing Total revision of Roux-en-Y gastric bypass in people with Obesity and Obesity-related Medical Conditions, run by Linkoeping University at 1 site in Sweden.
Trial summary
The majority of those who undergo gastric bypass surgery have a good/sufficient weight loss, averaging 25-30% after 10-20 years (Adams TD NEJM -18). In a subgroup analysis in LABS, 5% of RYGB patients had an unfavourable weight development with an average of only up to 10% weight loss 7 years after surgery (Courcoulas… Read more about this study
- Who is it for?
- Ages 25 to 60 years
- Conditions the study is for
- Obesity and Obesity-related Medical Conditions
- What is being tested?
- Total revision of Roux-en-Y gastric bypass
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteSweden
- Study dates
- 1 Feb 2025to 31 Jan 2035
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Body weight within 10% of initial weight
- >2 year after primary Roux-en-Y gastric bypass procedure
- Able to comprehend intended benefits and risks
- Understand the Swedish language
- Not responding sufficiently to life style intervention
- Be aware about available pharmacological interventions
Who cannot join
- Inflammatory bowel disease
- Below 25 or above 60 years of age
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Dept of Surgery, Vrinnevi hospital
Norrköping, Östergötland County
About this study
Official title: REDO- A Novel Surgical Revision Technique for Suboptimal Weight Loss or Recurrent Weight Gain After Roux-en-Y Gastric Bypass
The majority of those who undergo gastric bypass surgery have a good/sufficient weight loss, averaging 25-30% after 10-20 years (Adams TD NEJM -18). In a subgroup analysis in LABS, 5% of RYGB patients had an unfavourable weight development with an average of only up to 10% weight loss 7 years after surgery (Courcoulas et al, JAMA Surg -18). These data are in good agreement with data in the Scandinavian quality registry SOReg where 5-10% an insufficient weight loss/weight recurrence 10 years after gastric bypass (SOReg annual report -20).
Insufficient weight loss/weight recurrence after gastric bypass can for the individual, in addition to the negative effects on quality of life, mean that comorbidities to obesity are insufficiently controlled or recur. This applies not least to weight-related problems, such as osteoarthritis in the lower extremities where joint replacement surgery can be prevented by too high a body weight.
Read more
In summary, one in ten patients who undergo bariatric surgery with the gastric bypass method will therefore have an insufficient effect of the procedure in the long term. The first-line treatment is a review of what can be done with diet and exercise, which, however, usually has a very limited effect. In recent years, the addition of medications has become an alternative, but the effect is variable and insufficiently studied over a longer period of time. These medications are also not included in the high-cost coverage.
The surgical method that has so far gained the most popularity in gastric bypass reoperation is the so-called "distal gastric bypass". In distal gastric bypass, the part of the intestine where much of the nutrient absorption occurs is so short that all nutrients (fat) are not fully absorbed. Although this method can be effective for weight loss, it often has significant side effects such as diarrhea and deficiencies of minerals and fat-soluble vitamins.
Over the past decade, knowledge about the mechanism of action of gastric bypass surgery has increased significantly. It is primarily changes in hunger and satiety signals from the gastrointestinal system to the brain that lead to sustained weight loss. Studies have shown that poorer weight loss is associated with a weaker response to satiety signals compared to those who lose more than average weight, where instead the response is strong.
Based on knowledge of the importance of satiety signals, initial experiences have been gained with a new type of revision surgery to amplify the effect in satiety signalling in gastric bypass patients with inadequate weight control. The results of these surgeries have generally been positive, even if not all achieved significant weight loss.
This project will systematically study whether a new type of revision surgery is safe and sufficiently effective to achieve the desired weight loss and improve comorbidity in patients who have responded inadequately or regained weight after gastric bypass surgery.
Read the detailed description
This project aims to scientifically evaluate the risk/benefit ratio of a new type of reoperation/revision surgery for patient experiencing either a primarily poor response or late weight regain after Roux-en-Y gastric bypass surgery.
The scientific questions are:
Does the new surgical reconstruction lead to further weight loss? The primary endpoint for "successful" surgery is weight loss >10% of body weight 2 years after surgery.
What improvements in obesity comorbidities (e.g. type 2 diabetes, hypertension, dyslipidemia, sleep apnea, quality of life) can be achieved ?
Is the new surgical method associated with specific surgical risks and complications?
Is the new surgical method associated with an increased risk of nutritional deficiencies compared to primary gastric bypass?
Is the ability to eat and the bowel function affected in any way by the new surgical method?
An overall assessment will be made between investigators and the Data Safety and Monitoring Committee as to whether the positive effects of the procedure are sufficient in relation to the risks of the surgery.
Method:
We will conduct a case series with of 12 (6+6) gastric bypass patients with the new surgical method to achieve further weight loss and improved health.
Patients who have undergone gastric bypass surgery and have insufficient treatment effect (current weight <10% below the weight at the primary surgery) are identified at the outpatient clinic at the Department of Surgery, Vrinnevi Hospital in Norrköping. A clinically motivated investigation is carried out according to routine including a follow through X-ray to identify any anatomical defects in the gastric bypass construction or a gastro-gastric fistula.
If nothing abnormal emerges, it is further ensured that the patients have completed the usual intervention with lifestyle factors (diet and exercise) for optimized effect of the surgery. Patients will be informed that there are pharmacological treatments for weight loss (new drugs that are, however, not included in the high-cost coverage for this indication).
If, after the above, there is an agreement in the multidisciplinary team that revision surgery may be indicated and interest in treatment for the purpose of weight loss remains, the patients are asked about interest in participating in this study.
Patients will be thoroughly informed verbally during an outpatient visit and receive written research person information and plenty of time to ask questions. After a reasonable time for reflection and the opportunity to ask supplementary questions, an informed consent is signed if the attitude remains positive.
Basic investigation and supplementary study-specific information with validated questionnaires are obtained:
- Information about eating-related symptoms and so-called "dumping" with DSS (Dumping Severity Score)
- Information about gastrointestinal symptoms with GSRS (Gastrointestinal Symptom Rating Score)
- Blood samples in the quality registry SOReg are taken according to clinical routine as well as clinical information about, for example, current diseases and medication.
The usual preoperative preparation for the procedure then takes place, including at least 2 weeks of low calorie diet for preoperative weight loss. The keyhole surgical procedure includes:
- The entire gastric bypass construction is exposed and released from any adhesions. All limbs of the small intestine are measured and assessed for quality.
- All or parts of the first part of the intestine (the so-called Roux limb) is resected. The reason is that parts of the intestine may be of poor quality (for example, affected by adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine.
All or parts of the first part of the Roux-limb will be preserved if necessary to avoid having a too short total intestine length.
The gastric pouch should be small (<30 ml).
A new gastric bypass construction is constructed where the Roux limb is 1 meter long, and the small intestine section from the bypassed stomach is at least 1.5 meters long.
During the operation it is verified that the common limb (with full nutrient absorption) is at least 3 meters long to avoid malnutrition.
. The operation is performed under general anesthesia and the time for the operation itself is estimated to be between 90 and 120 minutes. After surgery, the patient is mobilized freely and is allowed to drink freely. Normally, the patient is discharged from the ward the day after the operation if everything has been uncomplicated. Sick leave is estimated to be between 2 and 3 weeks. Progress of the diet to regular solid food takes place over a month according to routine for primary gastric bypass surgery.
How does the project differ from standard care:
Usually health care is cautious about further surgical interventions in patients having regained weight after gastric bypass. However, revision surgeries such as "distal gastric bypass" or other surgical reconstructions have been performed in some clinics.
The surgical method to be studied in this project takes into account recently achieved knowledge about the mechanism of action of gastric bypass surgeries. By resecting the first part of the small intestine (1-1.5 meters) and performing a "new gastric bypass", this leads to:
- The food becomes exposed to more distal small intestine. Distal exposure is associated with increased release of gastrointestinal hormones (including GLP-1 and PYY). These gastrointestinal hormones signal satiety acts via the hypothalamus, and this is a central mechanism of action in gastric bypass. Patients with poor weight loss after gastric bypass have been shown to have a weak response in this mechanism and those with good weight loss have strong signalling.
- bile and gastric juices in the so-called "bilio-pancreatic limb" that connects the bypassed part of the stomach with the small intestine are lengthened. This has also been shown to be associated with increased release of gastrointestinal hormones (GLP-1, PYY) and greater weight loss. Bile and gastric juices in the intestine without concomitant food is a strong trigger for the release of satiety signals.
- Any flaw in the primary gastric bypass construction that could contribute to an "incorrect" eating pattern (more sweet, fatty and liquid calories which is associated with weight gain) is corrected.
- The absolute majority of the small intestine is preserved in the abdominal cavity and restoration of the anatomy is possible.
Previous experience with the intervention:
In a case series, conducted as a pilot project at Sahlgrenska University hospital in Gothenburg, Sweden the responsible researcher has operated on a dozen patients with total revision of the gastric bypass construction. Most often, it was a combined situation with suspected dysfunction of the gastric bypass and unsatisfactory weight effect. In those who were operated on with the new technique, the weight dropped on average from 127 to 101 kg (range for weight loss 2-54 kg) with varying follow-up times of up to several years. The patients' subjective assessment was: Two had unsatisfactory weight development (no or very limited weight loss, but no longer continued weight gain), The others were partially or completely satisfied with their weight development.
One patient had a lot of adhesions around the small intestine in connection with the revision surgery and developed adhesions again, which is why he ultimately needed surgery to restore normal anatomy after gastric bypass. Restoring normal anatomy is therefore still possible after this type of revision surgery, as at most 1-1.5 m of the length of the small intestine (normal length 6-11 m) is resected.
In none of the cases that underwent total revision did we note a tendency to nutritional deficiencies beyond what is seen after primary gastric bypass. No serious surgical complications arose in connection with the pilot series.
Data collection:
- weight, height, waist circumference, blood pressure
- inventory of comorbidities (e.g. medication for diabetes, high blood pressure, high blood lipids, sleep apnea, joint problems, inflammation).
- blood tests for comorbidities (fasting blood sugar, HbA1c, insulin, blood lipids, hs-CRP and blood status.
- blood sampling for vitamins and minerals.
- questionnaires for quality of life (standard for bariatric surgery)
- additional study-specific questionnaires for eating function and dumping (DSS) and gastrointestinal function (GSRS)
- Being tested
- Total revision of Roux-en-Y gastric bypass
- Keywords
- revisional bariatric surgery, Roux-en-Y gastric bypass
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Total revision of Roux-en-Y gastric bypassProcedure or surgery
- The entire previous gastric bypass construction is released from any adhesions and all parts of the small intestine are measured and assessed.
- All or parts of the first part of the intestine that food reaches after the gastric pouch (so-called Roux) is resected. The reason is that parts of the intestine that are considered to be of poor quality (for example, affected by a lot of adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine. The gastric pouch will be small (<30 ml).
- A new gastric bypass construction is constructed where the intestine receiving food from the esophagus (Roux) will be 1 meter, and the small intestine part from the closed stomach at least 1.5 meters.
The remaining length of the small intestine below the jejuno-jejunal anastomosis should be minimum 3 meters.
| Study group | Role | What they receive |
|---|---|---|
| Total revision of Roux-en-Y gastric bypass | Experimental | A complete revision of the previously performed Roux-en-Y gastric bypass Receives: Procedure: Total revision of Roux-en-Y gastric bypass |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight loss (kg)
We will consider the experimental procedure effective provided that 80% of participants lose at least 10% of preoperative weight
Measured: 2 years
Secondary outcomes (8)
Complication to surgery
Peri- or postoperative complications
Measured: 2 years
Side effects to the gastro-intestinal reconstruction
Diarrhoea, malnutrition
Measured: 2 years
Change in obesity comorbidity
Diabetes mellitus type 2, Hypertension, Hyperlipidemia, Obstructive Sleep Apnea, Joint pain
Measured: 2 years
Waist circumference
In centimeter. Measured between lowest rib and iliac anterior/superior spina
Measured: 2 years
Change in physical quality of life
RAND36 (Research AND Development). Four subscales measured from 0-100 where a higher score is better.
Measured: 2 years
Change in mental quality of life
RAND36 (Research AND Development). Four subscales from 0-100 where a higher score is better.
Measured: 2 years
Patient Reported Experience Measure
As measured in the Scandinavian Obesity Surgery Registry (SOReg)
Measured: 2 years
Nutritional deficienies
Blood concentrations and proportion of participants having abnormal levels of Vitamin D, Ionized Calcium, Vitamin B12, Folate, Iron, Ferritin, Total Iron Binding Capacity, Albumin.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2025
- Study start1 Feb 2025
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jan 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity and Obesity-related Medical ConditionsStudies of the same condition, open and under way.
- More trials run by Linkoeping UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Efficacy and safety study
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Linkoeping University
- Sponsor type
- Other government
- Collaborators
- Region Östergötland
- Responsible party
- Principal investigator, Torsten Olbers, Linkoeping University
- Investigators
- Torsten Olbers, Professor, Principal investigator, Linkoeping University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06857578
- Sponsor's protocol ID
- 2024-07210-01
- Acronym
- REDO
- Status last verified
- Feb 2025
- First submitted
- 18 Feb 2025
- Last updated
- 4 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data protection legislation in Sweden
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REDO- A Novel Surgical Revision Technique for Suboptimal Weight Loss or Recurrent Weight Gain After Roux-en-Y Gastric Bypass
- ClinicalTrials.gov ID
- NCT06857578
- Acronym / sponsor ID
- REDO / 2024-07210-01
- Keywords
- revisional bariatric surgery, Roux-en-Y gastric bypass
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Linkoeping UniversityOther government
- Collaborators
- Region Östergötland
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jan 2035 (estimated)
- First posted
- 4 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The majority of those who undergo gastric bypass surgery have a good/sufficient weight loss, averaging 25-30% after 10-20 years (Adams TD NEJM -18). In a subgroup analysis in LABS, 5% of RYGB patients had an unfavourable weight development with an average of only up to 10% weight loss 7 years after surgery (Courcoulas et al, JAMA Surg -18). These data are in good agreement with data in the Scandinavian quality registry SOReg where 5-10% an insufficient weight loss/weight recurrence 10 years after gastric bypass (SOReg annual report -20).
Insufficient weight loss/weight recurrence after gastric bypass can for the individual, in addition to the negative effects on quality of life, mean that comorbidities to obesity are insufficiently controlled or recur. This applies not least to weight-related problems, such as osteoarthritis in the lower extremities where joint replacement surgery can be prevented by too high a body weight.
In summary, one in ten patients who undergo bariatric surgery with the gastric bypass method will therefore have an insufficient effect of the procedure in the long term. The first-line treatment is a review of what can be done with diet and exercise, which, however, usually has a very limited effect. In recent years, the addition of medications has become an alternative, but the effect is variable and insufficiently studied over a longer period of time. These medications are also not included in the high-cost coverage.
The surgical method that has so far gained the most popularity in gastric bypass reoperation is the so-called "distal gastric bypass". In distal gastric bypass, the part of the intestine where much of the nutrient absorption occurs is so short that all nutrients (fat) are not fully absorbed. Although this method can be effective for weight loss, it often has significant side effects such as diarrhea and deficiencies of minerals and fat-soluble vitamins.
Over the past decade, knowledge about the mechanism of action of gastric bypass surgery has increased significantly. It is primarily changes in hunger and satiety signals from the gastrointestinal system to the brain that lead to sustained weight loss. Studies have shown that poorer weight loss is associated with a weaker response to satiety signals compared to those who lose more than average weight, where instead the response is strong.
Based on knowledge of the importance of satiety signals, initial experiences have been gained with a new type of revision surgery to amplify the effect in satiety signalling in gastric bypass patients with inadequate weight control. The results of these surgeries have generally been positive, even if not all achieved significant weight loss.
This project will systematically study whether a new type of revision surgery is safe and sufficiently effective to achieve the desired weight loss and improve comorbidity in patients who have responded inadequately or regained weight after gastric bypass surgery.
Detailed description
This project aims to scientifically evaluate the risk/benefit ratio of a new type of reoperation/revision surgery for patient experiencing either a primarily poor response or late weight regain after Roux-en-Y gastric bypass surgery.
The scientific questions are:
Does the new surgical reconstruction lead to further weight loss? The primary endpoint for "successful" surgery is weight loss >10% of body weight 2 years after surgery.
What improvements in obesity comorbidities (e.g. type 2 diabetes, hypertension, dyslipidemia, sleep apnea, quality of life) can be achieved ?
Is the new surgical method associated with specific surgical risks and complications?
Is the new surgical method associated with an increased risk of nutritional deficiencies compared to primary gastric bypass?
Is the ability to eat and the bowel function affected in any way by the new surgical method?
An overall assessment will be made between investigators and the Data Safety and Monitoring Committee as to whether the positive effects of the procedure are sufficient in relation to the risks of the surgery.
Method:
We will conduct a case series with of 12 (6+6) gastric bypass patients with the new surgical method to achieve further weight loss and improved health.
Patients who have undergone gastric bypass surgery and have insufficient treatment effect (current weight <10% below the weight at the primary surgery) are identified at the outpatient clinic at the Department of Surgery, Vrinnevi Hospital in Norrköping. A clinically motivated investigation is carried out according to routine including a follow through X-ray to identify any anatomical defects in the gastric bypass construction or a gastro-gastric fistula.
If nothing abnormal emerges, it is further ensured that the patients have completed the usual intervention with lifestyle factors (diet and exercise) for optimized effect of the surgery. Patients will be informed that there are pharmacological treatments for weight loss (new drugs that are, however, not included in the high-cost coverage for this indication).
If, after the above, there is an agreement in the multidisciplinary team that revision surgery may be indicated and interest in treatment for the purpose of weight loss remains, the patients are asked about interest in participating in this study.
Patients will be thoroughly informed verbally during an outpatient visit and receive written research person information and plenty of time to ask questions. After a reasonable time for reflection and the opportunity to ask supplementary questions, an informed consent is signed if the attitude remains positive.
Basic investigation and supplementary study-specific information with validated questionnaires are obtained:
- Information about eating-related symptoms and so-called "dumping" with DSS (Dumping Severity Score)
- Information about gastrointestinal symptoms with GSRS (Gastrointestinal Symptom Rating Score)
- Blood samples in the quality registry SOReg are taken according to clinical routine as well as clinical information about, for example, current diseases and medication.
The usual preoperative preparation for the procedure then takes place, including at least 2 weeks of low calorie diet for preoperative weight loss. The keyhole surgical procedure includes:
- The entire gastric bypass construction is exposed and released from any adhesions. All limbs of the small intestine are measured and assessed for quality.
- All or parts of the first part of the intestine (the so-called Roux limb) is resected. The reason is that parts of the intestine may be of poor quality (for example, affected by adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine.
All or parts of the first part of the Roux-limb will be preserved if necessary to avoid having a too short total intestine length.
The gastric pouch should be small (<30 ml).
A new gastric bypass construction is constructed where the Roux limb is 1 meter long, and the small intestine section from the bypassed stomach is at least 1.5 meters long.
During the operation it is verified that the common limb (with full nutrient absorption) is at least 3 meters long to avoid malnutrition.
. The operation is performed under general anesthesia and the time for the operation itself is estimated to be between 90 and 120 minutes. After surgery, the patient is mobilized freely and is allowed to drink freely. Normally, the patient is discharged from the ward the day after the operation if everything has been uncomplicated. Sick leave is estimated to be between 2 and 3 weeks. Progress of the diet to regular solid food takes place over a month according to routine for primary gastric bypass surgery.
How does the project differ from standard care:
Usually health care is cautious about further surgical interventions in patients having regained weight after gastric bypass. However, revision surgeries such as "distal gastric bypass" or other surgical reconstructions have been performed in some clinics.
The surgical method to be studied in this project takes into account recently achieved knowledge about the mechanism of action of gastric bypass surgeries. By resecting the first part of the small intestine (1-1.5 meters) and performing a "new gastric bypass", this leads to:
- The food becomes exposed to more distal small intestine. Distal exposure is associated with increased release of gastrointestinal hormones (including GLP-1 and PYY). These gastrointestinal hormones signal satiety acts via the hypothalamus, and this is a central mechanism of action in gastric bypass. Patients with poor weight loss after gastric bypass have been shown to have a weak response in this mechanism and those with good weight loss have strong signalling.
- bile and gastric juices in the so-called "bilio-pancreatic limb" that connects the bypassed part of the stomach with the small intestine are lengthened. This has also been shown to be associated with increased release of gastrointestinal hormones (GLP-1, PYY) and greater weight loss. Bile and gastric juices in the intestine without concomitant food is a strong trigger for the release of satiety signals.
- Any flaw in the primary gastric bypass construction that could contribute to an "incorrect" eating pattern (more sweet, fatty and liquid calories which is associated with weight gain) is corrected.
- The absolute majority of the small intestine is preserved in the abdominal cavity and restoration of the anatomy is possible.
Previous experience with the intervention:
In a case series, conducted as a pilot project at Sahlgrenska University hospital in Gothenburg, Sweden the responsible researcher has operated on a dozen patients with total revision of the gastric bypass construction. Most often, it was a combined situation with suspected dysfunction of the gastric bypass and unsatisfactory weight effect. In those who were operated on with the new technique, the weight dropped on average from 127 to 101 kg (range for weight loss 2-54 kg) with varying follow-up times of up to several years. The patients' subjective assessment was: Two had unsatisfactory weight development (no or very limited weight loss, but no longer continued weight gain), The others were partially or completely satisfied with their weight development.
One patient had a lot of adhesions around the small intestine in connection with the revision surgery and developed adhesions again, which is why he ultimately needed surgery to restore normal anatomy after gastric bypass. Restoring normal anatomy is therefore still possible after this type of revision surgery, as at most 1-1.5 m of the length of the small intestine (normal length 6-11 m) is resected.
In none of the cases that underwent total revision did we note a tendency to nutritional deficiencies beyond what is seen after primary gastric bypass. No serious surgical complications arose in connection with the pilot series.
Data collection:
- weight, height, waist circumference, blood pressure
- inventory of comorbidities (e.g. medication for diabetes, high blood pressure, high blood lipids, sleep apnea, joint problems, inflammation).
- blood tests for comorbidities (fasting blood sugar, HbA1c, insulin, blood lipids, hs-CRP and blood status.
- blood sampling for vitamins and minerals.
- questionnaires for quality of life (standard for bariatric surgery)
- additional study-specific questionnaires for eating function and dumping (DSS) and gastrointestinal function (GSRS)
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Efficacy and safety study
| Arm | Type | Receives |
|---|---|---|
| Total revision of Roux-en-Y gastric bypass | Experimental | Procedure: Total revision of Roux-en-Y gastric bypassA complete revision of the previously performed Roux-en-Y gastric bypass |
Who may qualify
- Ages
- 25 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Body weight within 10% of initial weight
- >2 year after primary Roux-en-Y gastric bypass procedure
- Able to comprehend intended benefits and risks
- Understand the Swedish language
- Not responding sufficiently to life style intervention
Key exclusion criteria (2 listed)
- Inflammatory bowel disease
- Below 25 or above 60 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Total revision of Roux-en-Y gastric bypass1. The entire previous gastric bypass construction is released from any adhesions and all parts of the small intestine are measured and assessed. 2. All or parts of the first part of the intestine that food reaches after the gastric pouch (so-called Roux) is resected. The reason is that parts of the intestine that are considered to be of poor quality (for example, affected by a lot of adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine. The gastric pouch will be small (<30 ml). 3. A new gastric bypass construction is constructed where the intestine receiving food from the esophagus (Roux) will be 1 meter, and the small intestine part from the closed stomach at least 1.5 meters. The remaining length of the small intestine below the jejuno-jejunal anastomosis should be minimum 3 meters. | Procedure or surgery | Total revision of Roux-en-Y gastric bypass |
Primary outcome
Weight loss (kg)
Time frame: 2 years
We will consider the experimental procedure effective provided that 80% of participants lose at least 10% of preoperative weight
8 secondary outcomes
Complication to surgery
Time frame: 2 years
Side effects to the gastro-intestinal reconstruction
Time frame: 2 years
Change in obesity comorbidity
Time frame: 2 years
Waist circumference
Time frame: 2 years
Change in physical quality of life
Time frame: 2 years
Change in mental quality of life
Time frame: 2 years
Patient Reported Experience Measure
Time frame: 2 years
Nutritional deficienies
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2025.
- Individual participant dataSharing planned: No. Data protection legislation in Sweden
Related trials for Obesity and Obesity-related Medical Conditions
Recruiting
Transition to Ambulatory Bariatric Surgery (TABS) Trial
Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Active, not recruitingEarly Phase 1
Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
Obesity and Obesity-related Medical Conditions
Recruiting
A Wearable Device and AI-Supported Diet and Exercise Intervention
Obesity and Obesity-related Medical Conditions
Recruiting
Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF)
Appetite, Obesity and Obesity-related Medical Conditions
Active, not recruitingPhase 4
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Obesity and Obesity-related Medical Conditions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Torsten Olbers, Professor principal investigator
Linkoeping University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Total revision of Roux-en-Y gastric bypass in people with Obesity and Obesity-related Medical Conditions, run by Linkoeping University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight loss (kg) (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2025.